XPO1 and acute myeloid leukemia: However, XPO7 knockdown has been implicated as a probable therapeutic target in conjunction with XPO1 knockdown in various neurodegenerative diseases such as dementia, amyotrophic lateral sclerosis (AML) and ovarian cancer and its overexpression in cancer results in poor outcomes [53,54].